The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Main finding · Composite cardiovascular eventsResult — go to the resultHazard ratio 0.88 95% CI 0.68–1.13Authors' conclusion
GLP-1RAs had a neutral effect on the composite cardiovascular outcomes but reduced composite kidney events in the patients with advanced DKD compared with DPP-4is.
Study context
- Population
- Patients with T2D and estimated glomerular filtration rate (eGFR) < 30 mL/min per 1.73 m² (advanced diabetic kidney disease (DKD)), first prescription 2012–2021; mean (SD) age 68.4 (11.5) years, 50.6% maleseligible
- Participants
- 8,922 patients
- Exposure
- GLP-1 RA vs DPP-4i
- GLP-1RAsn = 759
- DPP-4isn = 8,163reference
- Outcome
- Composite:
- Cardiovascular events
- Composite kidney events
- Follow-up
- Mean 2.1 years
Main finding
Composite cardiovascular events
Hazard ratio
0.88
95% CI 0.68–1.13
Events by group
GLP-1RAsvs DPP-4is
HR 0.88 (95% CI 0.68–1.13)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | GLP-1RAs | DPP-4is | Subdistribution HR (95% CI) | |
|---|---|---|---|---|
| Composite kidney events · mean follow-up 2.1 years | 38.2% | 44.2% | 0.72 (0.56–0.93) | |
| 0.512Subdistribution hazard ratio (log scale) |
Original publication
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovasc Diabetol. Published 17 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →